

# Daniel R Kuritzkes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/572702/publications.pdf>

Version: 2024-02-01

106  
papers

4,891  
citations

101543

36  
h-index

106344

65  
g-index

112  
all docs

112  
docs citations

112  
times ranked

7778  
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. <i>Clinical Infectious Diseases</i> , 2022, 75, e450-e458.	5.8	84
2	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
3	Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa. <i>HIV Medicine</i> , 2022, 23, 727-737.	2.2	2
4	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1389-1396.	5.8	9
5	Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746.	3.9	35
6	Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV. <i>HIV Medicine</i> , 2022, 23, 936-946.	2.2	12
7	Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1191-1200.	4.7	122
8	Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. <i>Clinical Infectious Diseases</i> , 2021, 72, 388-393.	5.8	17
9	Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. <i>ACS Nano</i> , 2021, 15, 665-673.	14.6	21
10	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. <i>Clinical Infectious Diseases</i> , 2021, 73, e997-e1003.	5.8	11
11	Impact of pre-existing drug resistance on risk of virological failure in South Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1558-1563.	3.0	13
12	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab153.	0.9	20
13	Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. <i>Aids</i> , 2021, 35, 1333-1342.	2.2	90
14	COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. <i>AIDS Research and Therapy</i> , 2021, 18, 28.	1.7	59
15	Adaptive adversarial neural networks for the analysis of lossy and domain-shifted datasets of medical images. <i>Nature Biomedical Engineering</i> , 2021, 5, 571-585.	22.5	15
16	Bamlanivimab for Prevention of COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 31.	7.4	13
17	Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e234-e236.	2.1	13
18	Patterns of pretreatment drug resistance mutations of very early diagnosed and treated infants in Botswana. <i>Aids</i> , 2021, 35, 2413-2421.	2.2	6

#	ARTICLE	IF	CITATIONS
19	38. Remdesivir Treatment in Patients Hospitalized with COVID-19: A Comparative Analysis of In-Hospital All-Cause Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, S27-S28.	0.9	0
20	Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 170.	4.1	2
21	Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25849.	3.0	5
22	Is France Once Again Looking for a Scapegoat?. <i>Pathogens and Immunity</i> , 2021, 6, 149-152.	3.1	1
23	Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. <i>Clinical Infectious Diseases</i> , 2020, 70, 1636-1642.	5.8	27
24	New Perspectives on the Virologic Consequences of M184V or I in Human Immunodeficiency Virus-1 Reverse Transcriptase. <i>Journal of Infectious Diseases</i> , 2020, 222, 1067-1069.	4.0	1
25	SARS-CoV-2 viral load is associated with increased disease severity and mortality. <i>Nature Communications</i> , 2020, 11, 5493.	12.8	702
26	Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 235-241.	2.1	12
27	Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy. <i>Translational Medicine Communications</i> , 2020, 5, .	1.4	1
28	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. <i>Nature</i> , 2020, 582, 438-442.	27.8	136
29	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1837-1842.	4.0	3
30	HIV diagnostic algorithm requires confirmatory testing for initial indeterminate or positive screens in the first week of life. <i>Aids</i> , 2020, 34, 1029-1035.	2.2	2
31	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. <i>Lancet HIV</i> , the, 2020, 7, e193-e200.	4.7	41
32	Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 268-282.	1.1	21
33	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , the, 2019, 6, e259-e268.	4.7	139
34	Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	74
35	Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 585-593.	2.1	14
36	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , the, 2019, 6, e116-e127.	4.7	84

#	ARTICLE	IF	CITATIONS
37	The Sloth. <i>Pathogens and Immunity</i> , 2019, 4, 195.	3.1	0
38	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 109-115.	0.5	6
39	Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 125-135.	2.1	59
40	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2018, 5, e146-e154.	4.7	61
41	Resistance to Dolutegravir—A Chink in the Armor?. <i>Journal of Infectious Diseases</i> , 2018, 218, 673-675.	4.0	4
42	DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics. <i>Nature Communications</i> , 2018, 9, 4282.	12.8	72
43	Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation. <i>PLoS ONE</i> , 2018, 13, e0197298.	2.5	6
44	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1412-1416.	5.2	2
45	Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana. <i>Journal of the International AIDS Society</i> , 2018, 21, e25111.	3.0	14
46	Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone. <i>ACS Nano</i> , 2018, 12, 5709-5718.	14.6	86
47	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963.	4.0	130
48	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. <i>Journal of Clinical Investigation</i> , 2018, 128, 4074-4085.	8.2	67
49	Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. <i>PLoS Pathogens</i> , 2018, 14, e1006856.	4.7	70
50	High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. <i>EBioMedicine</i> , 2017, 20, 217-229.	6.1	50
51	Global HIV Antiretroviral Drug Resistance. <i>Journal of Infectious Diseases</i> , 2017, 216, S798-S800.	4.0	25
52	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. <i>Journal of Infectious Diseases</i> , 2017, 216, 254-262.	4.0	41
53	Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens. <i>Nanoscale</i> , 2017, 9, 1852-1861.	5.6	58
54	Why cure, why now?. <i>Journal of Medical Ethics</i> , 2017, 43, 67-70.	1.8	17

#	ARTICLE	IF	CITATIONS
55	Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx138.	0.9	13
56	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	8.4	186
57	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. <i>PLoS ONE</i> , 2017, 12, e0181357.	2.5	31
58	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. <i>PLoS Pathogens</i> , 2017, 13, e1006478.	4.7	45
59	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. <i>Pathogens and Immunity</i> , 2017, 2, 376.	3.1	36
60	Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. <i>Pathogens and Immunity</i> , 2017, 2, 431.	3.1	12
61	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner". <i>Pathogens and Immunity</i> , 2016, 1, 154.	3.1	35
62	Humoral Immune Pressure Selects for HIV-1 CXCR4-chemokine Receptor 4-using Variants. <i>EBioMedicine</i> , 2016, 8, 237-247.	6.1	22
63	Evolution of coreceptor utilization to escape CCR5 antagonist therapy. <i>Virology</i> , 2016, 494, 198-214.	2.4	8
64	Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. <i>Antiviral Therapy</i> , 2016, 22, 71-75.	1.0	11
65	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. <i>AIDS and Behavior</i> , 2016, 20, 2983-2995.	2.7	5
66	Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men. <i>Journal of Infectious Diseases</i> , 2016, 213, 771-775.	4.0	17
67	Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. <i>PLoS Pathogens</i> , 2016, 12, e1005535.	4.7	85
68	Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva. <i>Scientific Reports</i> , 2015, 5, 9919.	3.3	25
69	The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. <i>Aids</i> , 2015, 30, 1.	2.2	214
70	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). <i>Aids</i> , 2015, 29, 2419-2426.	2.2	18
71	Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32. <i>Aids</i> , 2015, 29, 867-876.	2.2	26
72	Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2015, 10, e0139474.	2.5	25

#	ARTICLE	IF	CITATIONS
73	Differential Levels of Soluble Inflammatory Markers by Human Immunodeficiency Virus Controller Status and Demographics. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu117.	0.9	54
74	Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td ( States of America, 2015, 112, E4354-63.	7.1	56
75	Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets. <i>Scientific Reports</i> , 2015, 5, 8719.	3.3	148
76	Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e90485.	2.5	27
77	Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu018.	0.9	7
78	Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. <i>Aids</i> , 2014, 28, 181-186.	2.2	63
79	Micro-a-fluidics ELISA for Rapid CD4 Cell Count at the Point-of-Care. <i>Scientific Reports</i> , 2014, 4, 3796.	3.3	85
80	Nanostructured Optical Photonic Crystal Biosensor for HIV Viral Load Measurement. <i>Scientific Reports</i> , 2014, 4, 4116.	3.3	144
81	Lab-on-Chip: Acute On-Chip HIV Detection Through Label-Free Electrical Sensing of Viral Nano-Lysate (Small 15/2013). <i>Small</i> , 2013, 9, 2478-2478.	10.0	0
82	Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. <i>Journal of Infectious Diseases</i> , 2013, 208, 884-891.	4.0	53
83	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2013, 207, 1694-1702.	4.0	250
84	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naive Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. <i>PLoS ONE</i> , 2013, 8, e83514.	2.5	45
85	HAART for HIV-1 Infection: Zeroing In on When to Start. <i>Archives of Internal Medicine</i> , 2011, 171, 1569.	3.8	3
86	AIDS Clinical Trials Group 5197: A Placebo-Controlled Trial of Immunization of HIV-1-Infected Persons with a Replication-Deficient Adenovirus Type 5 Vaccine Expressing the HIV-1 Core Protein. <i>Journal of Infectious Diseases</i> , 2010, 202, 705-716.	4.0	106
87	Development of a microfluidic system for measuring HIV-1 viral load. <i>Proceedings of SPIE</i> , 2010, 7666, 76661H.	0.8	7
88	Integrating microfluidics and lensless imaging for point-of-care testing. , 2009, , .		1
89	Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2008, 197, 867-870.	4.0	170
90	Domain 4 of ILY sensitizes antibody therapy on cancer and HIV through abrogating human CD59 function. <i>FASEB Journal</i> , 2008, 22, 522-522.	0.5	5

#	ARTICLE	IF	CITATIONS
91	Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s. <i>Journal of Infectious Diseases</i> , 2007, 195, 1169-1176.	4.0	40
92	HIV resistance: frequency, testing, mechanisms. <i>Topics in HIV Medicine: A Publication of the International AIDS Society, USA</i> , 2007, 15, 150-4.	2.9	5
93	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	1.0	18
94	Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy. <i>Antiviral Therapy</i> , 2007, 12, 981-986.	1.0	24
95	Amdoxovir versus Placebo with Enfuvirtide plus Optimized Background Therapy for HIV-1-Infected Subjects Failing Current Therapy (Aactg A5118). <i>Antiviral Therapy</i> , 2006, 11, 619-623.	1.0	21
96	Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. <i>Antiviral Therapy</i> , 2006, 11, 751-760.	1.0	13
97	Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection. <i>Antiviral Therapy</i> , 2005, 10, 13-28.	1.0	24
98	Quantification of Human Immunodeficiency Virus Type 1 by Reverse Transcriptase-Coupled Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 2004, 190, 2047-2054.	4.0	3
99	Ethical Conduct of Research in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2004, 189, 764-765.	4.0	5
100	Preventing and Managing Antiretroviral Drug Resistance. <i>AIDS Patient Care and STDs</i> , 2004, 18, 259-273.	2.5	47
101	Extending antiretroviral therapy to resource-poor settings. <i>Aids</i> , 2004, 18, S45-S48.	2.2	10
102	Cardiovascular Risk Factors and Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2003, 348, 679-680.	27.0	23
103	Management of patients with virologic and metabolic failure. <i>Aids Reader</i> , 2003, 13, S17-22.	0.3	0
104	Effect of antiretroviral resistance on response in treatment-experienced patients. <i>Aids Reader</i> , 2003, 13, S5-11.	0.3	10
105	Early Intensification with Abacavir in Subjects at High Risk for Incomplete Viral Suppression. <i>Antiviral Therapy</i> , 2003, 8, 361-363.	1.0	1
106	Drug resistance. Navigating resistance pathways. <i>Aids Reader</i> , 2002, 12, 395-400, 407.	0.3	3